222 related articles for article (PubMed ID: 38325898)
1. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
Burge DJ; Werth VP; Boackle SA; Posada J
Lupus Sci Med; 2024 Feb; 11(1):. PubMed ID: 38325898
[TBL] [Abstract][Full Text] [Related]
2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
3. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R;
Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377
[TBL] [Abstract][Full Text] [Related]
4. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
[TBL] [Abstract][Full Text] [Related]
5. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
Furie RA; Bruce IN; Dörner T; Leon MG; Leszczyński P; Urowitz M; Haier B; Jimenez T; Brittain C; Liu J; Barbey C; Stach C
Rheumatology (Oxford); 2021 Nov; 60(11):5397-5407. PubMed ID: 33956056
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
[TBL] [Abstract][Full Text] [Related]
7. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
Touma Z; Gladman DD; Ibañez D; Taghavi-Zadeh S; Urowitz MB
J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488
[TBL] [Abstract][Full Text] [Related]
8. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
Bruce IN; van Vollenhoven RF; Psachoulia K; Lindholm C; Maho E; Tummala R
Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36639192
[TBL] [Abstract][Full Text] [Related]
9. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
Furie R; Morand EF; Bruce IN; Isenberg D; van Vollenhoven R; Abreu G; Pineda L; Tummala R
Arthritis Rheumatol; 2021 Nov; 73(11):2059-2068. PubMed ID: 33913260
[TBL] [Abstract][Full Text] [Related]
10. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
[TBL] [Abstract][Full Text] [Related]
11. Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures.
Thanou A; James JA; Arriens C; Aberle T; Chakravarty E; Rawdon J; Stavrakis S; Merrill JT; Askanase A
Lupus Sci Med; 2019; 6(1):e000365. PubMed ID: 31921432
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
[TBL] [Abstract][Full Text] [Related]
13. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E; Pike M; Merrill JT; van Vollenhoven R; Werth VP; Hobar C; Delev N; Shah V; Sharkey B; Wegman T; Catlett I; Banerjee S; Singhal S
Arthritis Rheumatol; 2023 Feb; 75(2):242-252. PubMed ID: 36369798
[TBL] [Abstract][Full Text] [Related]
14. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
Bruce IN; Furie RA; Morand EF; Manzi S; Tanaka Y; Kalunian KC; Merrill JT; Puzio P; Maho E; Kleoudis C; Albulescu M; Hultquist M; Tummala R
Ann Rheum Dis; 2022 Jul; 81(7):962-969. PubMed ID: 35580976
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
[TBL] [Abstract][Full Text] [Related]
16. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Clowse ME; Wallace DJ; Furie RA; Petri MA; Pike MC; Leszczyński P; Neuwelt CM; Hobbs K; Keiserman M; Duca L; Kalunian KC; Galateanu C; Bongardt S; Stach C; Beaudot C; Kilgallen B; Gordon C;
Arthritis Rheumatol; 2017 Feb; 69(2):362-375. PubMed ID: 27598855
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
Morand EF; Furie RA; Bruce IN; Vital EM; Dall'Era M; Maho E; Pineda L; Tummala R
Lancet Rheumatol; 2022 Apr; 4(4):e282-e292. PubMed ID: 38288923
[TBL] [Abstract][Full Text] [Related]
19. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
Morand EF; Abreu G; Furie RA; Golder V; Tummala R
Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
[TBL] [Abstract][Full Text] [Related]
20. Novel evidence-based systemic lupus erythematosus responder index.
Furie RA; Petri MA; Wallace DJ; Ginzler EM; Merrill JT; Stohl W; Chatham WW; Strand V; Weinstein A; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1143-51. PubMed ID: 19714615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
